Blood pressure lowering and renin-angiotensin system blockade
Author:
- 1 July 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 21 (6) , S3-S7
Abstract
Angiotensin II (ANG II), the main effector peptide of the renin-angiotensin system (RAS), is implicated in the development of vascular, cardiac and renal pathologies. Considered to be central to the whole cardiovascular continuum, recent investigations have also established a role for ANG II in the recovery of the brain after cerebral insult. ANG II exerts its actions through two receptors: ANG II type 1 (AT1) and type 2 (AT2). Characterization of these receptors and their functions has led to an understanding of the role that ANG II plays in the body and has opened new avenues for therapeutic research. Investigations in animal models of hypertension, endothelial dysfunction, myocardial infarction, left ventricular hypertrophy and stroke have established the part that the ANG II receptors play in vascular, cardiac and cerebral pathologies using selective inhibitors of AT1 and AT2 receptors. The AT1 receptor mediates most of the deleterious effects of ANG II, such as vasoconstriction, endothelial damage and cell growth. Selective inhibition of the AT1 receptor not only inhibits these effects, but also leaves the AT2 receptor open to stimulation by ANG II. Among the many potential effects mediated by stimulation of the AT2 is the neuronal regeneration after injury and inhibition of pathological growth. Thus, AT1 receptor blockade appears to offer both active and passive therapeutic benefits. With high penetration through the blood-brain barrier, effective and selective inhibition of the AT1 receptor and prolonged duration of the receptor blockade for more than 24 h, telmisartan is strongly placed for the emerging therapeutic opportunities.Keywords
This publication has 32 references indexed in Scilit:
- Angiotensin II receptor antagonists role in arterial hypertensionJournal of Human Hypertension, 2002
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- Angiotensin type-1 receptor blockers in heart failureProgress in Cardiovascular Diseases, 2002
- Angiotensin and its AT2 receptor: new insights into an old systemRegulatory Peptides, 2001
- Review: The renin-angiotensin system in the brain: an updateJournal of the Renin-Angiotensin-Aldosterone System, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Beyond blood pressure: new roles for angiotensin IICellular and Molecular Life Sciences, 1999
- Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptorsJournal Of Hypertension, 1998
- Distribution of angiotensin II receptor subtypes in rat brain nucleiNeuroscience Letters, 1991
- Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statementAmerican Heart Journal, 1991